Effectiveness of interventions to enhance healing of chronic ulcers of the foot in diabetes: A systematic review

Diabetes/Metabolism Research and Reviews

Volumn 32, Issue , 2016, Pages 154-168

  Game, F L ^a   Apelqvist, J ^b   Attinger, C ^c   Hartemann, A ^d   Hinchliffe, R J ^e   Londahl M ^b   Price, P E ^f   Jeffcoate, W J ^g  

^a DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c GEORGETOWN UNIVERSITY   (United States)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f CARDIFF UNIVERSITY   (United Kingdom)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Diabetes; Diabetic foot; Dressing; Ulcer; Wound healing

Indexed keywords

ALGINIC ACID; ANTIINFECTIVE AGENT; CARBOXYMETHYLCELLULOSE; CLOSTRIDIAL COLLAGENASE; COLLAGENASE; FIBROBLAST GROWTH FACTOR; HERBACEOUS AGENT; ILOPROST; OXIDIZED REGENERATED CELLULOSE; OXYGEN; OZONE; PETROLATUM; PHENYTOIN; PLANT EXTRACT; PLATELET DERIVED GROWTH FACTOR; UNCLASSIFIED DRUG; VILDAGLIPTIN; TOPICAL ANTIINFECTIVE AGENT;

AMNION; ARTICLE; BARK; BIOCHEMISTRY; BIOENGINEERING; CHRONIC WOUND; CHRONIC WOUND RESECTION; CLINICAL EFFECTIVENESS; COMPRESSION THERAPY; CYTOLOGY; DEBRIDEMENT; DIABETIC FOOT; DRUG EFFECT; EXTRACORPOREAL LITHOTRIPSY; FIBROBLAST CULTURE; HUMAN; HYDROGEL; HYDROTHERAPY; KERATINOCYTE; LOW LEVEL LASER THERAPY; MAGGOT THERAPY; MAGNETOTHERAPY; NORMOTHERMIC THERAPY; OXYGEN THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHARP DEBRIDEMENT; SKIN FIBROBLAST; SKIN GRAFT; SPLIT THICKNESS SKIN GRAFT; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; THERAPY EFFECT; TOPICAL TREATMENT; ULCER HEALING; VACUUM ASSISTED CLOSURE; WOUND CARE; WOUND DRESSING; WOUND HEALING IMPAIRMENT; ADVERSE EFFECTS; BIOLOGICAL THERAPY; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; EVIDENCE BASED MEDICINE; EXPERIMENTAL THERAPY; HYPERBARIC OXYGEN THERAPY; LIMB SALVAGE; MICROBIOLOGY; MULTIMODALITY CANCER THERAPY; PERSONALIZED MEDICINE; SKIN DISEASES, INFECTIOUS; SKIN TRANSPLANTATION; SOFT TISSUE INFECTIONS; TRENDS; WOUND HEALING;

ANTI-INFECTIVE AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; BIOLOGICAL THERAPY; COMBINED MODALITY THERAPY; DEBRIDEMENT; DIABETIC FOOT; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERBARIC OXYGENATION; LIMB SALVAGE; PRECISION MEDICINE; SKIN DISEASES, INFECTIOUS; SKIN TRANSPLANTATION; SOFT TISSUE INFECTIONS; THERAPIES, INVESTIGATIONAL; WOUND HEALING;

EID: 84956838166     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2707     Document Type: Article

References (151)

1. Hinchliffe RJ, Valk GD, Apelqvist J, et al. A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev 2008; 24(Suppl 1): S119-44.
2. Game FL, Hinchliffe RJ, Apelqvist J, et al. A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev 2012; 28(Suppl 1): 119-41.
3. SIGN: critical appraisal: notes and checklists http://www.sign.ac.uk/methodology/checklists.html accessed 6th November 2014
4. Saap LJ, Falanga V. Debridement performance index and its correlation with complete closure of diabetic foot ulcers. Wound Repair Regen 2002; 10: 354-359.
5. Steed DL, Donohoe D, Webster MW, Lindsley L. Diabetic Ulcer Study Group. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J Am Coll Surg 1996; 183: 61-64.
6. Sherman RA. Maggot therapy for treating diabetic foot ulcers unresponsive to conventional therapy. Diabetes Care 2003; 26: 446-451.
7. Armstrong DG, Sala P, Short B, et al. Maggot therapy in "lower extremity hospice" wound care. J Am Podiatr Med Assoc 2005; 95: 254-257.
8. Paul AG, Ahmad NW, Ariff AM, et al. Maggot debridement therapy with Lucillia cuprina: a comparison with conventional debridement in diabetic foot ulcers. Int Wound J 2009; 6: 39-46.
9. Wang SY, Wang JN, Lv DC, Diao YP, Zhang Z. Clinical research on the bio-debridement effect of maggot therapy for treatment of chronically infected lesions. Orthop Surg 2010; 2(3): 201-6.
10. Caputo WJ, Beggs DJ, DeFede JL, Simm L, Dharma H. A prospective randomized controlled trial comparing hydrosurgery debridement with conventional surgical debridement in lower extremity ulcers. Int Wound J 2008; 5: 288-294.
11. Tallis A, Motley TA, Wunderlich RP, et al. Collagenase Diabetic Foot Ulcer Study Group Clinical and economic assessment of diabetic foot ulcer debridement with collagenase: results of a randomized controlled study. Clin Ther 2013; 35(11): 1805-20.
12. Apelqvist J, Ragnarson TG. Cavity foot ulcers in diabetic patients: a comparative study of cadexomer iodine ointment and standard treatment. An economic analysis alongside a clinical trial. Acta Derm Venereol 1996; 76: 231-235.
13. Jeffcoate WJ, Price PE, Phillips CJ, et al. Randomised controlled trial of the use of three dressing preparations in the management of chronic ulceration of the foot in diabetes. Health Technol Assess 2009; 13: 1-86.
14. Apelqvist J, Larsson J, Stenstrom A. Topical treatment of necrotic foot ulcers in diabetic patients: a comparative trial of DuoDerm and MeZinc. Br J Dermatol 1990; 123: 787-792.
15. Shukrimi A, Sulaiman AR, Halim AY, Azril A. A comparative study between honey and povidone iodine as dressing solution for Wagner type II diabetic foot ulcers. Med J Malaysia 2008; 63: 44-46.
16. Rehman E-U, Afzal MO, Ali A, Qureshi A-RZ-U-R, Rashid M. Comparison between honey and povidone-iodine/normal saline Dressing for management of Wagner' grade s I & II diabetic foot ulcers. Pak J Med Health Sci 2013; 7(4): 1082-108.
17. Jan WA, Shah H, Khan M, Fayaz M, Ullah N. Comparison of conventional pyodine dressing with honey dressing for the treatment of diabetic foot ulcers. J Postgrad Med Inst 2012; 26(4): 402-7.
18. Jull AB, Walker N, Deshpande S. Honey as a topical treatment for wounds. Database Syst Rev 2013; 2. Art. No.: CD005083. doi:10.1002/14651858.CD005083.pub3
19. Piaggesi A, Goretti C, Mazzurco S, et al. A randomized controlled trial to examine the efficacy and safety of a new super-oxidized solution for the management of wide postsurgical lesions of the diabetic foot. Int J Low Extrem Wounds 2010; 9: 10-15.
20. Krause FG, de Vries G, Meakin C, Kalia TP, Younger AS. Outcome of transmetatarsal amputations in diabetics using antibiotic beads. Foot Ankle Int 2009; 30: 486-493.
21. Donaghue VM, Chrzan JS, Rosenblum BI, et al. Evaluation of a collagen-alginate wound dressing in the management of diabetic foot ulcers. Adv Wound Care 1998; 11: 114-119.
22. Lalau JD, Bresson R, Charpentier P, et al. Efficacy and tolerance of calcium alginate versus Vaseline gauze dressings in the treatment of diabetic foot lesions. Diabetes Metab 2002; 28: 223-229.
23. Piaggesi A, Baccetti F, Rizzo L, et al. Sodium carboxyl-methyl-cellulose dressings in the management of deep ulcerations of diabetic foot. Diabet Med 2001; 18: 320-324.
24. Jude EB, Apelqvist J, Spraul M, Martin J. Prospective randomized controlled study of Hydrofiber dressing containing ionic silver or calcium alginate dressings in non-ischaemic diabetic foot ulcers. Diabet Med 2007; 24: 280-288.
25. Muthukumarasamy MG, Sivakumar G, Manoharan G. Topical phenytoin in diabetic foot ulcers. Diabetes Care 1991; 14: 909-911.
26. Pai MR, Sitaraman N, Kotian MS. Topical phenytoin in diabetic ulcers: a double blind controlled trial. Indian J Med Sci 2001; 55: 593-599.
27. Ahmed A, Ahmed MI. A comparison of efficacy of topical use of phenytoin and Vaseline gauze dressing with Vaseline gauze dressing alone in healing of diabetic foot ulcers. J Postgrad Med Inst 2014; 28(3): 297-302.
28. Shaw J, Hughes CM, Lagan KM, et al. The effect of topical phenytoin on healing in diabetic foot ulcers: a randomized controlled trial. Diabet Med 2011; 28(10): 1154-7.
29. Jensen JL, Seeley J, Gillin B. Diabetic foot ulcerations. A controlled, randomized comparison of two moist wound healing protocols: carrasyn hydrogel wound dressing and wet-to-moist saline gauze. Adv Wound Care 1998; 11: S1-S4.
30. Cangialosi CP. Synthetic skin. A new adjunct in the treatment of diabetic ulcers. J Am Podiatry Assoc 1982; 72: 48-52.
31. Capasso VA, Munro BH. The cost and efficacy of two wound treatments. AORN J 2003; 77: 984-992.
32. Jacobs AM, Tomczak R. Evaluation of Bensal HP for the treatment of diabetic foot ulcers. Adv Skin Wound Care 2008; 21: 461-465.
33. Viswanathan V, Kesavan R, Kavitha KV, Kumpatla S. A pilot study on the effects of a polyherbal formulation cream on diabetic foot ulcers. Indian J Med Res 2011; 134: 168-73.
34. Li S, Zhao J, Liu J, et al. Prospective randomized controlled study of a Chinese herbal medicine compound Tangzu Yuyang ointment for chronic diabetic foot ulcers: a preliminary report. J Ethnopharmacol 2011; 133: 543-550.
35. Wang F1, Yuan N, Wang Y, et al. Clinical study on topical bismuth subgallate/borneol (Suile) dressing for treatment of diabetic foot ulcers. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2012; 26(8): 955-60.
36. 3-A(1-7) stimulation of diabetic foot ulcer healing: results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial. Wound Rep Reg 2012; 20: 482-490.
37. Solway DR1, Clark WA, Levinson DJ. A parallel open-label trial to evaluate microbial cellulose wound dressing in the treatment of diabetic foot ulcers. Int Wound J 2011; 8(1): 69-73.
38. Lima MH, Caricilli AM, de Abreu LL, et al. Topical insulin accelerates wound healing in diabetes by enhancing the AKT and ERK pathways: a double-blind placebo-controlled clinical trial. PLoS One 2012; 7(5): e36974.
39. Piaggesi A, Schipani E, Campi F, et al. Conservative surgical approach versus non-surgical management for diabetic neuropathic foot ulcers: a randomized trial. Diabet Med 1998; 15: 412-417.
40. Armstrong DG, Rosales MA, Gashi A. Efficacy of fifth metatarsal head resection for treatment of chronic diabetic foot ulceration. J Am Podiatr Med Assoc 2005; 95: 353-356.
41. Armstrong DG, Lavery LA, Vazquez JR, et al. Clinical efficacy of the first metatarsophalangeal joint arthroplasty as a curative procedure for hallux interphalangeal joint wounds in patients with diabetes. Diabetes Care 2003; 26: 3284-3287.
42. Leslie CA, Sapico FL, Ginunas VJ, Adkins RH. Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers. Diabetes Care 1988; 11: 111-115.
43. Heng MC, Harker J, Bardakjian VB, Ayvazian H. Enhanced healing and cost-effectiveness of low-pressure oxygen therapy in healing necrotic wounds: a feasibility study of technology transfer. Ostomy Wound Manage 2000; 46: 52-60.
44. Blackman E, Moore C, Hyatt J, Railton R, Frye C. Topical wound oxygen therapy in the treatment of severe diabetic foot ulcers: a prospective controlled study. Ostomy Wound Manage 2010; 56(6): 24-31.
45. Faglia E, Favales F, Aldeghi A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care 1996; 19: 1338-1343.
46. Kessler L, Bilbault P, Ortega F, et al. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care 2003; 26: 2378-2382.
47. Doctor N, Pandya S, Supe A. Hyperbaric oxygen therapy in diabetic foot. J PostgradMed 1992; 38: 112-114.
48. Abidia A, Laden G, Kuhan G, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double blind randomised-controlled trial. Eur J Vasc Endovasc Surg 2003; 25: 513-518.
49. Duzgun AP, Satir HZ, Ozozan O, et al. Effect of oxygen therapy on healing of diabetic foot ulcers. J Foot Ankl Surg 2008; 47: 515-519.
50. Löndahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care 2010; 33: 998-1003.
51. Khandelwal S, Chaudhary P, Poddar DD, et al. Comparative study of different treatment options of grade III and IV diabetic foot ulcers to reduce the incidence of amputations. Clinics and Practice 2013; 3: e9 20-24.
52. Ma L, Li P, Shi Z, et al. A prospective, randomized, controlled study of hyperbaric oxygen therapy: effects on healing and oxidative stress of ulcer tissue in patients with a diabetic foot ulcer. Ostomy Wound Manage 2013; 59(3): 18-24.
53. Wang CJ, Wu RW. Yang YJ treatment of diabetic foot ulcers: a comparative study of extracorporeal shockwave therapy and hyperbaric oxygen therapy. Diabetes Res Clin Pract 2011; 92(2): 187-93.
54. Wang CJ1, Kuo YR, Wu RW, et al. Extracorporeal shockwave treatment for chronic diabetic foot ulcers. J Surg Res 2009; 152(1): 96-103.
55. Margolis DJ, Gupta J, Hoffstad O, et al. Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation. A cohort study. Diabetes Care 2013; 36(7): 1961-6.
56. Carter MJ, Fife CE, Bennett M. Comment on: Margolis et al. lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: a cohort study. Diabetes Care 2013; 36: 1961-1966.
57. Löndahl M, Katzman P. Comments on Margolis et al. lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation. Int Wound J 2013. doi:10.1111/iwj.12093.
58. th November 2014)
59. Wainstein J, Feldbrin Z, Boaz M, Harman-Boehm I. Efficacy of ozone-oxygen therapy for the treatment of diabetic foot ulcers. Diabetes Technol Ther 2011; 13(12): 1255-60.
60. Armstrong DG, Nguyen HC. Improvement in healing with aggressive edema reduction after debridement of foot infection in persons with diabetes. Arch Surg 2000; 135: 1405-1409.
61. Akbari A, Moodi H, Ghiasi F, Sagheb HM, Rashidi H. Effects of vacuum compression therapy on healing of diabetic foot ulcers: randomized controlled trial. J Rehabil Res Dev 2007; 44: 631-636.
62. Mars M, Desai Y, Gregory MA. Compressed air massage hastens healing of the diabetic foot. Diabetes Technol Ther 2008; 10: 39-45.
63. Kavros SJ, Konstantinos TD, Turner NS, et al. Improving limb salvage in critical schaemia with intermittent pneumatic compression: a controlled study with18 month follow-up. J Vasc Surg 2008; 47: 543-549.
64. McCallon SK, Knight CA, Valiulus JP, et al. Vacuum-assisted closure versus saline-moistened gauze in the healing of postoperative diabetic foot wounds. Ostomy Wound Manage 2000; 46: 28-32.
65. Eginton MT, Brown KR, Seabrook GR, Towne JB, Cambria RA. A prospective randomized evaluation of negative-pressure wound dressings for diabetic foot wounds. Ann Vasc Surg 2003; 17: 645-649.
66. Armstrong DG, Lavery LA, Consortium DFS. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet 2005; 366: 1704-1710.
67. Sepulveda G, Espindola M, Maureira A, et al. Negative-pressure wound therapy versus standard wound dressing in the treatment of diabetic foot amputation. A randomised controlled trial. Cirurg Espanola 2009; 86: 171-177.
68. Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure wound therapy using vacuum assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers. Diabetes Care 2008; 31: 631-636.
69. Frykberg RG, Williams DV. Negative pressure wound therapy and diabetic foot amputations. J Am Podiatr Assoc 2007; 97: 351-359.
70. Nain PS, Uppal SK, Garg R, Bajaj K, Garg S. Role of negative pressure wound therapy in healing of diabetic foot ulcers. J Surg Tech Case Rep 2011; 3(1): 17-22.
71. Karatepe O, Eken I, Acet E, et al. Vacuum assisted closure improves the quality of life in patients with diabetic foot. Acta Chir Belg 2011; 111: 298-303.
72. Dalla Paola L, Carone A, Ricci S, et al. Use of vacuum assisted closure therapy in the treatment of diabetic foot wounds. J Diabetic Foot Complications 2010; 2(2): 33-44.
73. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 2002; 137: 822-827.
74. Lázaro-Martínez JL, García-Morales E, Beneit-Montesinos JV, Martínez-de-JesisFR Aragón-Sánchez FJ. Randomized comparative trial of a collagen/oxidized regenerated cellulose dressing in the treatment of neuropathic diabetic foot ulcers. Cirurg Esp 2007; 82: 27-31.
75. Kakagia DD, Kazakos KJ, Xarchas KC, et al. Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. J Diabetes Complications 2007; 21: 387-391.
76. Gottrup F, Cullen BM, Karlsmark T, et al. Randomized controlled trial on collagen/oxidized regenerated cellulose/silver treatment. Wound Rep Reg 2013; 21: 216-225.
77. Motzkau M, Tautenhahn J, Lehnert H, Lobmann R. Expression of matrix-metalloproteases in the fluid of chronic diabetic foot wounds treated with a protease absorbent dressing. Exp Clin Endocrinol Diabetes 2011; 119(5): 286-90.
78. Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care 2005; 18: 258-266.
79. Brigido SA. The use of an acellular dermal regenerative matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. Int Wound J 2006; 3: 161-167.
80. Reyzelman A, Crews RT, Moore L, et al. Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study. Int Wound J 2009; 6: 196-208.
81. Lyons TE, Miller MS, Serena T, et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. Am J Surg 2007; 193: 49-54.
82. Fife C, Mader JT, Stone J, et al. Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebocontrolled phase I/II study. Wound Repair Regen 2007; 15: 23-34.
83. Purandare H, Supe A. Immunomodulatory role of Tinospora cordifolia as an adjuvant in surgical treatment of diabetic foot ulcers: a prospective randomized controlled study. Indian J Med Sci 2007; 61: 347-355.
84. Squadrito F, Bitto A, Altavilla D, et al. The effect of PDRN, an adenosine receptor A2A agonist, on the healing of chronic diabetic foot ulcers: results of a clinical trial. J Clin Endocrinol Metab 2014; 99(5): E746-53.
85. Richard JL, Parer-Richard C, Daures JP, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care 1995; 18: 64-69.
86. Uchi H, Igarashi A, Urabe K, et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. Eur J Dermatol 2009; 19: 461-468.
87. nd April 2015)
88. Tsang MW, Wong WK, Hung CS, et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 2003; 26: 1856-1861.
89. Afshari M, Larijani B, Fadayee M, et al. Efficacy of topical epidermal growth factor in healing diabetic foot ulcers. Therapy 2005; 2: 759-765.
90. Viswanathan V, Pendsey S, Sekar N, Murthy GSR. A phase II study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-D ™ 150) in healing diabetic foot ulcers. Wounds 2006; 18: 186-196.
91. Fernandez-Montequin JI, Valenzuela-Silva CM, Diaz OG, et al. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicentre, randomised, placebo controlled, double-blind study. Int Wound J 2009; 6: 432-443.
92. Singla S, Singla S, Kumar A, Singla M. Role of epidermal growth factor in healing of diabetic foot ulcers. Indian J Surg 2012; 74(6): 451-455.
93. Kusumanto YH, Van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischaemia: a double-blind randomized trial. Human Gene Her 2006; 17: 683-691.
94. Gough A, Clapperton M, Rolando N, et al. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 1997; 350: 855-859.
95. de Lalla F, Pellizzer G, Strazzabosco M, et al. Randomized prospective controlled trial of recombinant granulocyte colony stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother 2001; 45: 1094-1098.
96. Yonem A, Cakir B, Guler S, Azal OO, Corakci A. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab 2001; 3: 332-337.
97. Kastenbauer T, Hornlein B, Sokol G, Irsigler K. Evaluation of granulocyte-colony stimulating factor (Filgrastim) in infected diabetic foot ulcers. Diabetologia 2003; 46: 27-30.
98. Huang P, Li S, Han M, et al. Autologous transplantation of granulocyte colony-stimulating factor mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005; 28: 2155-2160.
99. Steed DL, Group DUS. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995; 21: 71-78.
100. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998; 21: 822-827.
101. Robson MC, Payne WG, Garner WL, et al. Integrating the results of phase IV (post-marketing) clinical trial with four previous trials reinforces the position that Regranex (becaplermin) gel 0.01% is an effective adjunct to the treatment of diabetic foot ulcers. J Appl Res 2005; 5: 35-45.
102. Landsman A, Agnew P, Parish L, Joseph R, Galiano RD. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicentre, prospective analysis. J Am Podiatr Med Assoc 2010; 100(3): 155-160.
103. Krupski WC, Reilly LM, Perez S, et al. A prospective randomized trial of autologous platelet-derived wound healing factors for treatment of chronic nonhealing wounds: a preliminary report. J Vasc Surg 1991; 14: 526-532.
104. Steed DL, Goslen JB, Holloway GA, et al. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care 1992; 15: 1598-1604.
105. Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001; 24: 483-488.
106. Driver VR, Hanft J, Fylling CP, Beriou JM, Group ADFUS. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage 2006; 52: 68-70.
107. Feng J, Du WH, Wang J. Clinical study of various growth factors on the improvement of impaired healing ulcers in patients with diabetic disease. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 1999; 13: 273-277.
108. Jeong S-H, Han S-K, Kim W-K. Treatment of diabetic foot ulcers using a blood bank concentrate. Plast Reconstr Surg 2010; 125: 944-952.
109. Seung-Kyu H, Hong-Ryul K, Woo-Kyung K. The treatment of diabetic foot ulcers with uncultured, processed lipoaspirate cells: a pilot study. Wound Rep Reg 2010; 18: 342-346.
110. Gentzkow GD, Iwasaki SD, Hershon KS, et al. Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996; 19: 350-354.
111. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs 1997; 21: 1203-1210.
112. Marston WA, Hanft J, Norwood P, Pollak R, Group DDFUS. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003; 26: 1701-1705.
113. Veves A, Falanga V, Armstrong DG, Sabolinski ML, Study ADFU. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001; 24: 290-295.
114. Edmonds M. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds 2009; 8: 11-18.
115. Uccioli L, Giurato L, Ruotolo V, et al. Two-step autologous grafting using HYAFF scaffolds in treating difficult diabetic foot ulcers: results of a multicentre, randomized controlled clinical trial with long-term follow-up. Int J Low Extrem Wounds 2011; 10(2): 80-5.
116. Bayram Y, Deveci M, Imirzalioglu N, Soysal Y, Sengezer M. The cell based dressing with living allogenic keratinocytes in the treatment of foot ulcers: a case study. Br J Plast Surg 2005; 58: 988-996.
117. Moustafa M, Bullock AJ, Creagh FM, et al. Randomized, controlled, single blind study on use of autologous keratinocytes on a transfer dressing to treat nonhealing ulcers. Regen Med 2007; 2: 887-902.
118. You HJ1, Han SK, Lee JW, Chang H. Treatment of diabetic foot ulcers using cultured allogeneic keratinocytes - a pilot study. Wound Repair Regen 2012; 20(4): 491-9.
119. Mahmoud SM, Mohamed AA, Mahdi SE, Ahmed ME. Split-skin graft in the management of diabetic foot ulcers. J Wound Care 2008; 17: 303-306.
120. Jeon H, Kim J, Yeo H, et al. Treatment of diabetic foot ulcer using matriderm in comparison with a skin graft. Arch Plast Surg 2013; 40: 403-408.
121. Zelen CM. An evaluation of dehydrated human amniotic membrane allografts in patients with DFUs. J Wound Care 2013; 22(7): 347-8.
122. Baker LL, Chambers R, DeMuth SK, Villar F. Effects of electrical stimulation on wound healing in patients with diabetic ulcers. Diabetes Care 1997; 20: 405-412.
123. Peters EJ, Lavery LA, Armstrong DG, Fleischli JG. Electric stimulation as an adjunct to heal diabetic foot ulcers: a randomized clinical trial. Arch Phys Med Rehabil 2001; 82: 721-725.
124. Margara A, Boriani F, Obbialero FD, Bocciotti MA. Frequency rhythmic electrical modulation system in the treatment of diabetic ulcers. Chirurgia 2008; 21: 311-314.
125. Petrofsky JS, Lawson D, Berk L, Suh H. Enhanced healing of diabetic foot ulcers using local heat and electrical stimulation for 30 min three times a week. J Diabetes 2010; 2: 41-46.
126. Moretti B, Notamicola A, Maggio G, et al. The management of neuropathic ulcers of the foot in diabetes shock wave therapy. BMC Musculoskelet Disord 2009; 10: 54-61.
127. Alvarez OM, Rogers RS, Booker JG, Patel M. Effect of noncontact normothermic wound therapy on the healing of neuropathic (diabetic) foot ulcers: an interim analysis of 20 patients. J Foot Ankle Surg 2003; 42: 30-35.
128. Szor J, Holewinski P. Lessons learned in research: an attempt to study the effects of magnetic therapy. Ostomy Wound Manage 2002; 48: 24-29.
129. Chiglashvili DS, Istomin DA. Complex treatment of patients with the diabetic foot. Klin Med (Mosk) 2004; 82: 66-69.
130. Rullan M, Cerda L, Frontera G, Masmiquel L, Llobera J. Treatment of chronic diabetic foot ulcers with bemiparin: a randomized, triple blind, placebo-controlled, clinical trial. Diabet Med 2008; 25: 1090-1095.
131. Sert M, Soydas B, Aikimbaev T, Tetiker T. Effects of iloprost (a prostacyclin analogue) on the endothelial function and foot ulcers in diabetic patients with peripheral arterial disease. Int J Diabetes Metab 2008; 16: 7-11.
132. Leung PC, Wong MV, Wong WC. Limb salvage in extensive diabetic foot ulceration: an extended study using a herbal supplement. Hnk Kng Med J 2008; 14: 29-33.
133. Bahrami A, Kamali K, Ali-Asgharzadeh A, et al. Clinicall applications of oral form of ANGIPARSTM and in combination with topical form as a new treatment for diabetic foot ulcers: a randomized controlled trial. DARU 2008; 16(Suppl 1): S41-48.
134. Larijani B, Heshmat R, Bahrami A, et al. Effects of intravenous Semelil (ANGIPARS™) on diabetic foot ulcers healing: a multicentre clinical trial. DARU 2008; 16(Suppl 1): S35-40.
135. Marfella R, Sasso FC, Rizzo MR, et al. Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes. Exp Diabetes Res 2012, Article ID 892706. doi:10.1155/2012/892706.
136. Rewale V, Prabhakar KR, Chitale AM. Pentoxifylline: a new armamentarium in diabetic foot ulcers. J Clin Diagn Res 2014; 8(1): 84-6.
137. Dumville JC, Soares MO, O'Meara S, Cullum N. Systematic review and mixed treatment comparison: dressings to heal diabetic foot ulcers. Diabetologia 2012; 55(7): 1902-10.
138. NICE clinical guidelines. Diabetic foot problems: inpatient management of diabetic foot problems. https://www.nice.org.uk/guidance/cg119 (accessed 11th October 2015)
139. Dumville JC, Deshpande S, O'Meara S, Speak K. Hydrocolloid dressings for healing diabetic foot ulcers. Cochrane Database Syst Rev 2013; 8: CD009099. doi:10.1002/14651858.CD009099.pub3.
140. Dumville JC, O'Meara S, Deshpande S, Speak K. Hydrogel dressings for healing diabetic foot ulcers. Cochrane Database Syst Rev 2013; 7: CD009101. doi:10.1002/14651858.CD009101.pub3.
141. Dumville JC, O'Meara S, Deshpande S, Speak K. Alginate dressings for healing diabetic foot ulcers. Cochrane Database Syst Rev 2013; 6: CD009110. doi:10.1002/14651858.CD009110.pub3.
142. Dumville JC, Deshpande S, O'Meara S, Speak K. Foam dressings for healing diabetic foot ulcers. Cochrane Database Syst Rev 2013; 6: CD009111. doi:10.1002/14651858.CD009111.pub3.
143. Dumville JC, Hinchliffe RJ, Cullum N, et al. Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus. Cochrane Database Syst Rev 2013; 10: CD010318. doi:10.1002/14651858.CD010318.pub2.
144. Blackman JD, Senseng D, Quinn L, Mazzone T. Clinical evaluation of a semipermeable polymeric membrane dressing for the treatment of chronic diabetic foot ulcers. Diabetes Care 1994; 17: 322-325.
145. Tan JS, Friedman NM, Hazelton-Miller C, Flanagan JP, File TM Jr. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? Clin Infect Dis 1996; 23: 286-291.
146. Chen CE, Ko JY, Fong CY, Juhn RJ. Treatment of diabetic foot infection with hyperbaric oxygen. Int J Low Wounds 2010; 9: 10-15.
147. Di Mauro C, Ossino AM, Trefiletti M, Polosa P, Beghe F. Lyophilized collagen in the treatment of diabetic ulcers. Drugs Exp Clin Res 1991; 17: 371-373.
148. Tom WL, Peng DH, Allaei A, Hsu D, Hata TR. The effect of short contact topical tretinoin therapy for foot ulcers in patients with diabetes. Arch Dermatol 2005; 141: 1373-1377.
149. Seung-Kyu H, Hyon-Surk K, Woo-Kyung K. Efficacy and safety of fresh fibroblast allografts in the treatment of diabetic foot ulcers. Dermatol Surg 2009; 35: 1342-1348.
150. Puttirutvong P. Meshed skin graft versus split thickness skin graft in diabetic ulcer coverage. J Med Assoc Thai 2004; 87: 66-72.
151. Ennis WJ, Foremann P, Mozen N, et al. Ultrasound therapy for recalcitrant diabetic foot ulcers: results of a randomized, double-blind, controlled, multicenter study. Ostomy Wound Manage 2005; 51: 24-39.